Evaluation of Clinical Outcomes of Antiangiogenic-Targeted Therapy in Patients with Pulmonary Metastatic Renal Cell Carcinoma Using Non-Contrast-Enhanced Computed Tomography

Combined with changes to imaging parameters, including size, attenuation value, and uniformity between pre- and post-treatment, discrimination analysis can help predict biologic response to antiangiogenic drugs and provide a more accurate response assessment than RECIST criteria.